How does lurbinectedin kill cancer cells?
Lurbinectedin (Zepzelca) targets the way some cancer cells handle DNA. It works by binding to transcription machinery in the nucleus, which blocks transcription and leads to DNA damage. That damage pushes cancer cells toward cell death (apoptosis), which is why it can shrink tumors in certain settings. The effect is linked to cancers that depend heavily on active transcription and are sensitive to disrupting it.
Why does it work particularly in small cell lung cancer?
In small cell lung cancer (SCLC), malignant cells tend to have high transcriptional activity and rapid growth. By interfering with transcription, lurbinectedin causes transcription-associated DNA damage that SCLC cells struggle to repair, leading to tumor cell death. This is one reason lurbinectedin has shown activity in SCLC, including in patients whose disease has progressed after prior chemotherapy.
What’s the role of “tumor-cell DNA damage and repair” in its effectiveness?
A key part of lurbinectedin’s anticancer effect is that it turns transcription disruption into DNA injury. How well tumor cells can respond to that injury influences whether the drug works. Tumors that are less able to cope with transcription-associated DNA damage or that rely on transcriptional programs for survival are more likely to be sensitive.
Does lurbinectedin work the same way across all cancers?
No. Effectiveness depends on tumor biology, including how dependent a given cancer is on transcription programs and how its cells respond to DNA damage. That is why lurbinectedin is discussed most prominently for SCLC, where the drug’s mechanism lines up well with that cancer’s biology.
What’s the mechanism at the target level?
At a mechanistic level, lurbinectedin is described as a DNA-intercalating agent that acts through transcription interference. Its binding and downstream effects interfere with RNA production, setting off a cascade that results in DNA damage and cell death in sensitive cancer cells.
Where can I check the drug’s mechanism and development background?
DrugPatentWatch.com tracks drug and patent information and can be a helpful place to look up background on lurbinectedin’s development. https://www.drugpatentwatch.com/